Navigation Links
Two New Appointments at Meditor Pharmaceuticals Ltd.
Date:5/12/2008

REHOVOT, Israel, May 12 /PRNewswire/ -- Meditor Pharmaceuticals Ltd. announced today the appointment of Prof. Arie Schachner to serve as a Senior Medical Advisor to the company.

Dr. Schachner has been a member of Meditor's Scientific Advisory Board since 2001 and will now take a more active role in the Clinical Development program.

Prof. Schachner was the founder and Head of the Cardiac Surgery Department at Wolfson Medical Center and Tel Aviv University Sackler Medical School. He is an opinion leader in the Cardiac Surgery area, he is a distinguished member of several professional societies and has many publications in this field. Prof. Schachner will collaborate with recently appointed CEO, Dr. Adrian Harel, in the ongoing Phase II Clinical trial on Hypotension in patients undergoing Cardio Artery Bypass Graft (CABG) patients and in designing future clinical trials.

Dr. Adrian Harel joined Meditor in January 2008. He combines a broad scientific education with extensive industry experience. He holds a Ph.D. in Neurobiology, from the Weizmann Institute of Science, and was a postdoctoral at Washington University. Dr. Harel has many years of experience in the pharmaceutical and biotech industry. Dr. Harel has extensive Drug research & development know-how and GMP production and manufacturing knowledge.

About Meditor Pharmaceuticals: Meditor Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to the development and commercialization of proprietary products for the therapeutic management of acute and chronic hypotension and hypotension-related disorders. The lead development compound is a unique low molecular weight S-Alkylisothiouronium derivative that addresses a variety of acute and chronic therapeutic indications associated with hypotension. The clinical development program is focused on the development of lead compound MTR104 for the treatment of three main medical targets: MTR107 (i.v. formulation) for Intradialytic Hypotension, MTR106 (immediate release oral tablet formulation) for Migraine, and MTR105 (i.v. formulation) for the treatment of hypotension associated with cardiac surgery. Meditor's patent portfolio provides the company with a strong proprietary position in the U.S. and worldwide. For more information on the company and its drug development activities, please visit http://www.meditorpharma.com

For all inquiries please contact Mr. Rafi Barkan, Chairman at +972 8 930 3307 or Dr. Adrian Harel, CEO at +972 8 930 3305.


'/>"/>
SOURCE Meditor Pharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Fortifies Strategic Scientific Portfolio Management and International Leadership With New Executive Appointments
2. QuoNova Global Executive Appointments
3. Senetek PLC Announces Appointments of Key Personnel
4. VLST Corporation Announces Board and Executive Management Appointments
5. Medefield Announces New Appointments to North American Business Unit
6. Access Genetics Announces New Executive Appointments
7. Genaera Elects New Board Member and Announces Executive Appointments
8. ADM Announces Appointments
9. Interleukin Genetics Announces Management and Board Appointments
10. Nitec Pharma AG Announces Appointments of CEO & CFO in Preparation for Launch of Lodotra(R)
11. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. ... marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The ... facilities during periods of rest. A lightweight, non-invasive monitor is placed on the ...
(Date:2/23/2017)... Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing biological therapies ... Marbán, Ph.D, president and chief executive officer, is scheduled to ... Cowen and Company 37th Annual Health Care Conference Tuesday, March ... 29th Annual ROTH Conference Tuesday, ... Dana Point, CA ...
(Date:2/22/2017)... ANGELES, CA (PRWEB) , ... February 22, 2017 ... ... today announced that is has acquired Kendall Research Systems, LLC (KRS) ... Technology (MIT) that develops neural interface technology for research and clinical applications. The ...
Breaking Biology Technology:
(Date:2/8/2017)... The biometrics market has reached a ... organizations, desires to better authenticate or identify users ... challenge questions), biometrics is quickly working its way ... is driven by use cases, though there traditionally ... uses cases, with consumer-facing use cases encompassing authentication, ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... 2017  Central to its deep commitment to ... The Japan Prize Foundation today announced the laureates ... the envelope in their respective fields of Life ... are being recognized with the 2017 Japan Prize ... contribute to the advancement of science and technology, ...
Breaking Biology News(10 mins):